PRICE NEGOTIATIONS IN CONTEXT OF EARLY BENEFIT ASSESSMENT IN GERMANY- IS A FLAT PRICING MODEL FOR NEW DRUGS ENFORCEABLE?
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1996
https://www.valueinhealthjournal.com/article/S1098-3015(16)30281-9/fulltext
Section Title :
Health Care Use & Policy Studies - Health Care Costs & Management
Section Order :
1114
First Page :
A280
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)30281-9&doi=10.1016/j.jval.2016.03.1996